论文部分内容阅读
The process of developing novel anticancer agents has become more costly and lengthy than ever[1].In addition,agents that target de novo pathway not only put the patients to unpredictable toxicity but also increase the risk in drug development[2].Therefore,re-discovering the potential of decade-old drugs for novel anticancer therapeutics provides a new route for drug development.Thalidomide,rapamycin,and azacitidine exemplify the potential of this approach and many more,such as metformin,and valproic acid are in the process of validating their role as new anticancer agents[3,4].Now we have two more members to join the rank.Cardiac glycosides,which have been used to treat cardiac failure for decades,recently emerge as potential anti-cancer agents[5].A recent work by TAILLER et al took advantage of high thorough-put screening of 1040 FDA approved agents for antileukemic activity and identified ouabain and zinc pyrithione,which have been used in the past for treating heart failure and dermatologic diseases respectively,as novel antileukemic agents[6].